These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28321074)

  • 21. Epstein-Barr Virus-positive T-cell Lymphoproliferative Disease Following Umbilical Cord Blood Transplantation for Acute Myeloid Leukemia.
    Yui S; Yamaguchi H; Imadome K; Arai A; Takahashi M; Ohashi R; Tamai H; Moriya K; Nakayama K; Shimizu A; Inokuchi K
    J Nippon Med Sch; 2016; 83(1):35-42. PubMed ID: 26960588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Peric Z; Cahu X; Chevallier P; Brissot E; Malard F; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Milpied N; Coste-Burel M; Imbert-Marcille BM; Mohty M
    Leukemia; 2011 Jun; 25(6):932-8. PubMed ID: 21350556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-Cell-Rich T-Cell Lymphoma Associated with Epstein-Barr Virus-Reactivation and T-Cell Suppression Following Antithymocyte Globulin Therapy in a Patient with Severe Aplastic Anemia.
    Hanaoka N; Murata S; Hosoi H; Shimokado A; Mushino T; Kuriyama K; Hatanaka K; Nishikawa A; Kurimoto M; Sonoki T; Muragaki Y; Nakakuma H
    Hematol Rep; 2015 Sep; 7(3):5906. PubMed ID: 26487932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr virus associated aplastic anaemia and hepatitis.
    Lau YL; Srivastava G; Lee CW; Kwong KY; Yeung CY
    J Paediatr Child Health; 1994 Feb; 30(1):74-6. PubMed ID: 8148196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
    Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
    Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Post-transplant EBV-associated lymphoproliferative disorders--report of two cases].
    Iwami H; Misawa A; Tsunamoto K; Kasubuchi Y; Naya M; Hojo M; Goto T; Hibi S; Matsumura T; Todo S; Imashuku S
    Rinsho Ketsueki; 1998 Mar; 39(3):198-204. PubMed ID: 9577643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus-related lymphoproliferative disorder, cytomegalovirus reactivation, and varicella zoster virus encephalitis during treatment of medulloblastoma.
    Ohta M; Taga T; Nomura A; Kato H; Takano T; Maruo Y; Takeuchi Y; Ishida M; Ohta S
    J Med Virol; 2011 Sep; 83(9):1582-4. PubMed ID: 21739449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia].
    Yago K; Itoh M; Shimada H
    Rinsho Ketsueki; 2001 Nov; 42(11):1105-10. PubMed ID: 11808079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.
    Kato S; Miyata T; Takata K; Shimada S; Ito Y; Tomita A; Elsayed AA; Takahashi E; Asano N; Kinoshita T; Kimura H; Nakamura S
    Hum Pathol; 2013 Dec; 44(12):2849-52. PubMed ID: 24012167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
    Zhu K; Chen J; Chen S
    Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia.
    Buyck HC; Ball S; Junagade P; Marsh J; Chakrabarti S
    Bone Marrow Transplant; 2009 May; 43(10):813-6. PubMed ID: 19104495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of immunosuppression on the development of Epstein-Barr virus (EBV) viremia after pediatric liver transplantation.
    Lu BR; Park KT; Hurwitz M; Cox KL; Berquist WE
    Transplant Proc; 2013; 45(1):301-4. PubMed ID: 23267800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
    Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Ohto H; Kikuta A
    Pediatr Int; 2017 Sep; 59(9):973-978. PubMed ID: 28581032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation.
    Chiang KY; Hazlett LJ; Godder KT; Abhyankar SH; Christiansen NP; van Rhee F; Lee CG; Bridges K; Parrish RS; Henslee-Downey PJ
    Bone Marrow Transplant; 2001 Dec; 28(12):1117-23. PubMed ID: 11803352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning.
    Cohen J; Gandhi M; Naik P; Cubitt D; Rao K; Thaker U; Davies EG; Gaspar HB; Amrolia PJ; Veys P
    Br J Haematol; 2005 Apr; 129(2):229-39. PubMed ID: 15813851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
    Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.